Merck Millipore buys Amnis Corporation
The acquisition will complement EMD Millipore Guava flow cytometry product range
EMD Millipore, the life science division of Merck KGaA of Germany, has bought Amnis Corporation, a manufacturer of advanced cell imaging systems for an undisclosed sum.
The deal is subject to regulatory approvals and is expected to close in the fourth quarter.
The acquisition will complement EMD Millipore’s Guava flow cytometry product range. It will also allow Seattle, US-based Amnis to expand via EMD Millipore's global footprint, reagent expertise and r&d resources.
Amnis generated sales of US$14m (€10m) in 2010 and has maintained a compound annual growth rate in excess of 80% since 2005.
‘The acquisition of Amnis significantly contributes to our strategy to be a leader in cellular analysis and systems biology by providing access to Amnis’ novel imaging and image analysis technology, as well as its truly unique product line of instruments that combine high-speed imaging with flow cytometry,’ said Jonathan DiVincenzo, head of the Bioscience business unit within EMD Millipore.
David Basiji, co-founder and chief executive of Amnis, said: ‘The combination of Amnis with EMD Millipore will greatly accelerate development of novel applications in imaging flow cytometry, enhance our customer support, and accelerate product development.’
